The STAR trial was a phase III, double-blind trial that screened 184,480
There was no effect of raloxifene on the risk of stroke in the MORE trial
Design, setting, participants, and interventions: STAR was a double-blind
65 %, and 19,747 were subsequently
The Study of Tamoxifen and Raloxifene (STAR trial) for the prevention of breast cancer Hawaii Med J
12 This trial, started in
Tamoxifen is used mainly to treat hormone receptor-positive breast cancer (breast cancer with cells that have estrogen and/or progesterone receptors on them)
Raloxifene was found to be equivalent to tamoxifen in reducing the incidence of breast cancer but with fewer risks
In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either oral tamoxifen (20 mg/day) or raloxifene (60 mg/day) over 5 years
The May 1999 opening of the Study of Tamoxifen and Raloxifene (STAR) trial followed closely on the heels of the NSABP's first breast cancer prevention trial, in which researchers found that women at high risk of breast cancer who took tamoxifen experienced a 49% decrease in the incidence of invasive breast cancer compared to those who did not
We would like to show you a description here but the site won’t allow us
Consistent with The results of the STAR trial documented that tamoxifen and raloxifene were equally effective in reducing the risk of invasive breast cancer (risk ratio, 1
STAR was a multi-center, randomized clinical trial of oral tamoxifen 20 mg/day or oral raloxifene 60 mg/day for a maximum of 5 years, among 19,747 postmenopausal women 35 years of age or older at increased risk for breast cancer according to the modified Gail model
Tamoxifen is typically taken daily by mouth for five years for breast cancer